GEM Weekly (8 Apr 2022): South Korea, China, India Macro Data; JD.com, Tencent, Chinese Audits
The Global Emerging Markets weekly provides a summary of the key news and related developments impacting the largest countries and constituents of...
481 Views
China ADRs Delisting - Tide Is Turning with CSRC Showing Signs of a Compromise
On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas...
723 Views
Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”
After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and...
420 Views
New CSRC "Provisions" Take a Step Towards Meeting PCAOB Requirements
CSRC has published new Provisions putting the onus of info management on companies, making it easier for the PCAOB to conduct on-site audits. It...
483 Views
Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval
Going by the FDA’s recent action, Junshi Bioscience’s toripalimab has a chance to get rejected by the FDA. It may miss the approval timeline....
415 Views